Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Authors : Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart-Gebhart M, Suter T, de Azambuja E
Year : 2018
Journal : Breast Cancer Res Treat
Volume : 168(3)
Pages : 631-638

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Authors : Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E
Year : 2018
Journal : Eur J Cancer
Volume : 89
Pages : 42-48

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Authors : Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Ameye L, Piccart-Gebhart M, Bromberg JF, Sotiriou C
Year : 2018
Journal : Int J Oncol
Volume : 52(2)
Pages : 424-432

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Authors : Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M
Year : 2018
Journal : Cancer Treat Rev
Volume : 62
Pages : 123-132

Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.

Authors : Awada G, de Azambuja E, Awada A
Year : 2017
Journal : Expert Opin Drug Metab Toxicol
Volume : 13(12)
Pages : 1205-1215

Recurrence dynamics of breast cancer according to baseline body mass index.

Authors : Biganzoli E, Desmedt C, Fornili M, de Azambuja E, Cornez N, Ries F, Closon-Dejardin MT, Kerger J, Focan C, Di Leo A, Nogaret JM, Sotiriou C, Piccart-Gebhart M, Demicheli R
Year : 2017
Journal : Eur J Cancer
Volume : 87
Pages : 10-20

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Authors : Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : iv84-iv99

HER2-positive breast cancer is lost in translation: time for patient-centered research.

Authors : Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M
Year : 2017
Journal : Nat Rev Clin Oncol
Volume : 14(11)
Pages : 669-681

Male breast cancer: finding the way in this uncommon path.

Authors : Maurer C, Martel S, de Azambuja E
Year : 2017
Journal : ESMO Open
Volume : 2
Pages : e000169

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.

Authors : Kourie HR, El Rassy E, Clatot F, de Azambuja E, Lambertini M
Year : 2017
Journal : Onco Targets Ther
Volume : 10
Pages : 3363-3372

Systemic chemotherapy regimens in early breast cancer patients: updated recommendations from the BSMO breast cancer task force.

Authors : Wildiers H, Duhoux F, Awada A, de Azambuja E
Year : 2017
Journal : Belgian J Medical Oncology
Volume : 11(8)
Pages : 375-379

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Authors : Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M
Year : 2017
Journal : Cancer Treat Rev
Volume : 57
Pages : 8-15

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Authors : Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Year : 2017
Journal : J Clin Oncol
Volume : 35
Pages : 1421-1429

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Authors : Gingras I, Holmes E, de Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart-Gebhart M, Azim HA Jr
Year : 2017
Journal : J Natl Cancer Inst
Volume : 109

Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Authors : Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH
Year : 2017
Journal : Ann Oncol
Volume : 28(7)
Pages : 1590-1596

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.

Authors : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Piccart-Gebhart M
Year : 2017
Journal : PLoS One
Volume : 12(3)
Pages : e0172351

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stu

Authors : Zardavas D, Suter TM, van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart M, de Azambuja E
Year : 2017
Journal : J Clin Oncol
Volume : 35(8)
Pages : 878-884

Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.

Authors : Lambertini M, Del Mastro L, Viglietti G, Pondé NF, Solinas C, de Azambuja E
Year : 2017
Journal : Curr Treat Options Oncol
Volume : 18
Pages : 4

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Authors : Cameron D, Piccart-Gebhart M, Gelber Rd, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, Mcfadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C
Year : 2017
Journal : Lancet
Volume : 389(10075)
Pages : 1195-1205

The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.

Authors : Bozovic-Spasojevic I, Zardavas D, Brohée S, Ameye L, Fumagalli D, Ades F, de Azambuja E, Bareche Y, Piccart-Gebhart M, Paesmans M, Sotiriou C
Year : 2017
Journal : Clin Cancer Res
Volume : 23(11)
Pages : 2702-2712